GIOVANNI B. FRISONI

neurologist

 gfrisoni@fatebenefratelli.eu

 go to the full CV

  • Head of Neuroimaging and Epidemiology Unit, IRCCS Fatebenefratelli, Brescia – Italy
  • Full Professor of Clinical Neuroscience at the University of Geneva, Switzerland, and
  • Head of the Memory Clinic of the Geneva University Hospital.

SCIENTIFIC ACTIVITY: Brescia and  Ginevra
CLINICAL ACTIVITY: Geneva


Prof. Frisoni’s work is focused on new scientific discoveries on Alzheimer’s disease (in particular in neuroimaging) which might have immediate clinical effect to improve the diagnosis, the drug treatment and medication of patients with dementia.

Prof Frisoni is a Clinical neurologist. Former Scientific Director at the National Alzheimer’s Centre in Brescia, Italy, he leads a team of 25 imaging scientists in Italy and 10 scientists in Geneva. Author of over 500 scientific papers listed in PubMed, imaging editor for Neurobiology of Aging, and founding editorial board member of The Lancet Neurology. Has led national and international projects funded by the European Commission, the Alzheimer’s Association, Italian and Swiss Ministry of Health, and industry. Over the years, he has attracted over 25M euros in competitive research funds. Chairman of Alzheimer’s Imaging Consortium at International Conference on Alzheimer’s Disease in 2010 and 2011. Honorary member of the Austrian Neurological Society, has received the Lyons Career Award in 2013.

Principal Investigator of European Commission funded projects that led to the development of the neuGRID infrastructure for imaging neuroscientists based on cloud computing. Has brought ADNI to Europe with Alzheimer’s Association grant Pilot European ADNI in 2005-6 and IMI Pharmacog WP5/EADNI in 2010. Has brought ADNI and DIAN to Italy with Italian Ministry of Health-funded Italian ADNI (2010-12) and Italian DIAN (2012-ongoing). Has led the international Alzheimer’s Association Harmonized Protocol for Manual Hippocampal Segmentation. Has brought amyloid PET to Italy thanks to investigator-initiated sponsored studies with florbetapir, flutemetamol, and florbetaben and tau PET to Switzerland thanks to H2020 coSTREAM. National lead for Switzerland and Italy of IMI EPAD – European Prevention of Alzheimer’s Disease, leads the diagnostic branch of IMI2 AMYPAD, the amyloid PET chapter of EPAD.